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Abstract
Background: To evaluate whether tumor invasion depth can be a reliable and easily applicable pathologic
assessment strategy to predict outcomes using surgically resected cervical squamous cell carcinoma specimens
from patients who have received neoadjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT).
Methods: We included 173 patients with cervical squamous cell carcinoma who received neoadjuvant CCRT (n = 125)
or RT (n = 48) and underwent subsequent radical hysterectomy. Data for the pre-operative clinical International
Federation of Gynecology and Obstetrics (FIGO) stage, post-operative pathologic FIGO stage, World Health
Organization (WHO) double diameter measurement evaluation, response evaluation criteria in solid tumors (RECIST 1.1)
criteria, tumor necrosis rate (TNR), and tumor regression grade (TRG) were investigated to identify correlations with
outcomes related to distant metastasis and survival. The tumor invasion depth (TID) and the tumor invasion depth with
cytokeratin immunostaining correction (TIDC) at the cervical internal surface were measured to assess their relations to
patients’ outcomes.
Results: Based on measurements taken via transvaginal ultrasound, the pre-operative clinical and post-operative
pathologic FIGO staging as well as the WHO double diameter measurement evaluation and RECIST 1.1 criteria were
predictive of distant metastasis and survival-related outcomes. Also, lymph node involvement was found to be an
independent prognostic factor for recurrence and distant metastasis. Finally, univariate analysis showed both the TID
and TIDC were highly related to distant metastasis, overall survival, and progression-free survival, irrespective of the
clinical stage of carcinomas.
Conclusion: The TID or TIDC measured at the cervical internal surface is a useful and easily applied pathologic
prognostic factor for distant metastasis and survival outcomes in patients with cervical squamous cell carcinoma
treated with neoadjuvant RT or CCRT.
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Background
Cervical squamous cell carcinoma is one of the most com-
mon gynecological malignancies, affecting the health of
women worldwide [1, 2]. In China, cervical carcinoma is
the second most common gynecological malignancy [3].
The treatment strategy for cervical carcinoma has been
changed significantly in the past two decades [4, 5]. For
International Federation of Gynecology and Obstetrics
(FIGO) stage Ib and II patients, treatment involving neoad-
juvant therapies plus surgery have been shown to achieve
more benefits than surgery alone [6–8]. In addition, just as
we have observed in our clinical practice, previous studies
also have confirmed that even FIGO stage III b cervical car-
cinoma patients who receive neoadjuvant therapies are able
to endure surgical treatment with better outcomes [9–11].
Moreover, the use of neoadjuvant radiotherapy (RT) alone
or with concomitant chemoradiotherapy (CCRT) is effect-
ive for achieving excellent cervical carcinoma control along
with surgical resection [12, 13].
Pathologic findings in resected specimens of cervical car-
cinoma can be the basis for extremely accurate assessment
of the extent of disease [14, 15]. However, as neoadjuvant
RT and CCRT are applied in increasingly more cervical car-
cinoma patients, the need for a useful and easily applied
pathologic assessment becomes increasingly critical.
In the present study, we conducted a retrospective ana-
lysis of 173 cervical squamous cell carcinoma patients who
received neoadjuvant RT or CCRT with the objective of de-
termining whether the tumor invasion depth could be an
objectively, reproducibly, and quantitatively measured
pathologic parameter to predict these patients’ outcomes.
Methods
Patients
Between April 2006 and June 2011, 173 FIGO stage Ib2–
IIIb cervical carcinoma patients underwent radical hyster-
ectomy and pelvic lymph node dissection after neoadju-
vant RT (n = 48) or CCRT (n = 125) in the Xijing Hosptial,
Fourth Military Medical University. The interval between
pre-operative RT or CCRT and radical surgery was typic-
ally 2–3 weeks. The pathologic subtype in all cases was
squamous cell carcinoma. Patients’ complete information
was recorded in our department, and follow-up informa-
tion was obtained from electronic medical records or by
telephone interviews of patients between April 2006 and
December 2014.
And all the researches, including the different treatments,
the name of the patients and their outcomes, were per-
formed with the approval of an appropriate ethics commit-
tee of Fourth Military Medical University.
Cervical carcinoma staging
We evaluated target lesions via physical examination
and transvaginal ultrasound (TVS) examination, and
tumor size was measured according to images taken be-
fore surgery. Based on the 2009 FIGO staging system
[16, 17], the pre-operative clinical staging data included
primarily the size of the imaged tumor and observations
from physical examinations.
After surgery, tumor size and extent were evaluated by
pathologic examination. Post-operative staging was carried
out as “y” Pathologic stage according to 2009 FIGO sta-
ging system.
Tumor neoadjuvant treatment response evaluation
The tumor size was measured by TVS examination be-
fore RT and again before surgery, and the data were used
for evaluation by World Health Organization (WHO)
double diameter measurement [18] and the response
evaluation criteria in solid tumors (RECIST) 1.1 criteria
[19]. The microscopic residual tumor size was used to
evaluate the tumor necrosis rate (TNR) [20] and tumor
regression grade (TRG) evaluation.
Considering the change in tumor burden as an import-
ant feature in the clinical evaluation of cancer therapeu-
tics, the WHO double diameter measurement was
obtained as previously described [18]. Complete response
(CR) is defined as the disappearance of all target lesions,
and any pathological lymph nodes must be reduced to
having a short axis <10 mm. Partial response (PR) is
defined as at least a 50 % decrease in the products of
bidimensional lesion measurements of target lesions.
Progressive disease (PD) is defined as at least a 25 %
increase and stable disease (SD) is defined as tumor
shrinkage not sufficient to qualify as PR or tumor growth
not sufficient to qualify as PD.
The response evaluation criteria in solid tumors
(RECIST) 1.1 criteria [19] use a unidimensional measure
(the longest diameter) assessment of one or more target
lesions with summation of unidimensional assessments
of many lesions to quantify measurable tumor lesions.
CR requires a complete absence of disease, whereas PR
indicates a more than 30 % decrease in the sum of the
largest diameters. PD is defined by an increase in the
sum of the largest diameters by more than 20 %, and SD
represents all the outcomes between PR and PD.
The TNR [20] is defined as the presence of micro-
scopic coagulative necrosis, and the presence of necrosis
on gross examination was not considered. The extent of
tumor necrosis was assessed in a semiquantitative
manner at low magnification (magnification, ×40) of
all available tumor blocks. The TRG was recorded
according to a 5-grade scale: TRG 1 indicates absence
of residual cancer; TRG 2 indicates few residual cancer
cells; TRG 3 indicates a considerable number of
residual cancer cells; TRG 4 indicates outgrowth of
residual cancer; and TRG 5 indicates a lack of regres-
sive changes.
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Neoadjuvant RT and chemotherapy regimens
Pre-operative pelvic RT was delivered using three-
dimensional conformal radiation techniques and 6.0 or 15.0
medium voltage photons using a linear accelerator (Clinac
23EX or 600 C/D; Varian Medical Systems, Palo Alto, CA,
USA). Patients were immobilized in the supine position
using a custom vacuum mattress and first underwent a
computed tomography (CT) simulation scan (PQS +AcQ-
Sim; Philips, Amsterdam, The Netherlands) with intraven-
ous contrast, using 5.0-mm slice thickness. Simulation
images extended from L1 to 5.0 cm below the ischial tuber-
osities. The treatment planning was designed and com-
puted using the Plato system version 2.7.5 (Varian, Salt
Lake City, UT, USA). The pelvic irradiation dose was 40–
50 Gy in 20–25 fractions.
CCRT was administered to 121 patients via weekly intra-
venous infusion of cisplatin (40 mg/m2) during pelvic exter-
nal beam RT. Patients received either three (n = 30, 25 %),
four (n = 46, 38 %), or five (n = 45, 37 %) cycles of cisplatin.
Chemotherapy was withheld under the following condi-
tions: white blood cell count <2.0 × 109/L, absolute neutro-
phil count <1.0 × 109/L, platelet count <50 × 109/L, or
grade 3–4 radiation enteritis or cystitis.
The interval between pre-operative RT or CCRTand rad-
ical surgery was 3 weeks for 71 (41.0 %) patients, 2 weeks
for 93 (53.8 %) patients, and 1 week for only 9 (5.2 %)
patients.
Histopathologic examination and immumohistochemical
staining
The histopathologic response to neoadjuvant therapy was
evaluated based on pathologic examination of resected
specimens, including uterine tissue, the vaginal cuff, the
parametrium, bilateral adnexa, and pelvic lymph nodes.
The status of resected lymph nodes was described in terms
of lymph-node involvement (involved or not involved).
The pan-cytokeratin antibody (AE1/AE3) (Dako, Glostrup,
Denmark) was used in immunohistochemical staining
to identify any invisible residual tumor cells.
Measurement of TID
Pathologic examination of specimens removed by radical
hysterectomy was performed using a standardized process.
Briefly, each fresh surgical specimen was opened with a
scissor at the 12:00 o'clock position and pinned on a cork
plate with fixation overnight in 4 % buffered formalin. Then
the TID (in millimeters) was measured on the H&E stained
slides with the largest tumor area by two pathologists
blinded to the outcomes of the patients using magnifying
ruler. The TID was recognized as the longest tumor length
perpendicular to the cervical internal surface (Fig. 1a & 1b).
With the cytokeratin immunostaining correction, the TIDC
also was measured as the length perpendicular to the
cervical internal surface to the farmost residual tumor cells
identified by AE1/AE3 immunostaining (Fig. 1c).
Statistical analysis
Quantitative variables are presented as frequencies and
percentages, and the Chi-square test and Spearman test
were applied to assess associations between categorical
variables. Univariate analysis was first performed to
identify factors of strongest significance, followed by
step-wise stratified analysis and complemented with
multivariate analysis to define the best statistically sig-
nificant combination of these factors. Then multivariate
Cox proportional hazard models were applied to assess
the independent impacts of combined variables with dis-
tant metastasis, progression-free survival (PFS), and
overall survival (OS), followed by step-wise stratified
analysis beginning with the strongest factors.
Receiver operating characteristic (ROC) curves were cal-
culated to represent the relationship between true positive
events (sensitivity) and false positive events (100 – specifi-
city) for different cut-off points. Such ROC curves for
sensitivity and specificity are often used to assess the
performance of diagnostic tests, prognostic factors,
and classifiers.
Therefore, ROC curves were constructed for quantita-
tive variables to determine the best cut-off point values
discriminating between groups with good or poor prog-
nosis and to define the distinctions between groups with
differing prognosis.
OS and PFS were calculated from the date of diagnosis
to the date of the last follow-up. Death events in the ab-
sence of disease progression were censored in the calcu-
lation of PFS. Survival probabilities were calculated by
the Kaplan–Meier method and compared by the log-
rank test. A P-value of less than 0.05 was considered sta-
tistically significant in all tests, and all statistical analyses




The median age of all 173 patients was 46 years (range, 25–
71 years), and the majority of patients (150/173) had FIGO
stage IIb cervical carcinoma. Detailed data regarding patient
characteristics before and after radical hysterectomy are
presented in Table 1. Notably, the incidence rates of death
within 5 years of diagnosis (6/15, 40 %; P < 0.001) and the
development of distant metastasis (5/15, 33.3 %; P < 0.05)
were significantly greater in patients with stage IIIb cervical
carcinoma than in patients with carcinomas of other stages.
The results also showed that distant metastasis and death
occurred more frequently among patients who experienced
PR compared to CR, (P < 0.05 for WHO double diameter
measurement and the RECIST 1.1 evaluation). Finally,
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Table 1 The characteristics of 173 patients with FIGO stages Ib-IIIb cervical squamous cell carcinoma before and after the radical







P Recurrence, n (%) P The death events within
5 years, n (%)
P
Treatments CCRT 125(72.3 %) 45(25–65) 12(9.6 %) 0.579 4(3.2 %) 0.697 7(5.6 %) 0.512
RT 48(27.7 %) 46(34–71) 6(12.5 %) 1(2.1 %) 4(8.3 %)
FIGO stage Ib 5(2.9 %) 45(42–47) 0 0.003 0 0.319 0 <0.001
IIa 3(1.7 %) 45(38–58) 0 0 0
IIb 150(86.7 %) 45(27–71) 13(8.7 %) 4(2.7 %) 5(3.3 %)
IIIb 15(8.7 %) 48(25–65) 5(33.3 %) 1(6.7 %) 6(40 %)
yPathologic stage, * 84(48.6 %) 45(27–65) 3(3.6 %) 0.001 1(1.2 %) 0.150 1(1.2 %) 0.003
yI a1 24(13.9 %) 42(35–52) 2(8.3 %) 0 1(4.2 %)
yI a2 5(2.9 %) 43(32–57) 0 1(20 %) 1(20 %)
yI b2 61(35.2 %) 46(25–71) 13(21.3 %) 3(4.9 %) 8(13.1 %)
WHO evaluation CR 83(48.0 %) 45(27–65) 3(3.6 %) 0.007 1(1.2 %) 0.206 1(1.2 %) 0.010
PR 88(50.9 %) 45(25–65) 15(17.0 %) 4(4.5 %) 10(11.4 %)
SD 2(1.2 %) 57(43–71) 0 0 0
PD 0 0 0 0 0
RECIST1.1 CR 83(48.0 %) 45(27–65) 3(3.6 %) 0.005 1(1.2 %) 0.224 1(1.2 %) 0.007
PR 90(52.0 %) 45(25–71) 15(16.7 %) 4(4.4 %) 10(11.1 %)
SD 0 0 0 0 0
PD 0 0 0 0 0
TNR <90 % 102(59.0 %) 46(27–71) 11(10.8 %) 0.506 3(2.9 %) 0.789 8(7.8 %) 0.309
>90 % 71(41.0 %) 45(25–65) 7(9.9 %) 2(2.8 %) 3(4.2 %)
TRG TRG1 23(13.3 %) 46(36–58) 1(4.3 %) 0.176 0 0.925 0 0.119
TRG2 70(40.5 %) 45(27–71) 7(10 %) 3(4.3 %) 5(7.1 %)
TRG3 44(25.4 %) 44(25–65) 4(9.1 %) 1(2.3 %) 1(2.3 %)
TRG4 33(19.1 %) 47(30–65) 5(15.2 %) 1(3.0 %) 4(12.1 %)
TRG5 3(1.7 %) 45(39–45) 1(33.3 %) 0 1(33.3 %)
Lymph node metastasis yes 20(11.6 %) 46(37–65) 7(35.0 %) 0.000 3(15.0 %) 0.001 3(15.0 %) 0.093
no 153(88.4 %) 45(25–71) 11(7.2 %) 2(1.3 %) 8(5.2 %)
Note: Post-operative pathologic FIGO stage *: FIGO staging no longer includes Stage 0 (Tis)
Fig. 1 a Sketch illustrating the measurement method of tumor invasion depth (TID) at the cervical internal surface. b The red arrow indicates the
measurement of the TID at the cervical internal surface in a representative specimen (magnification, ×40). c The yellow arrow indicates the
measurement of TIDC at the cervical internal surface in a representative specimen with cytokeratin immunostaining correction (magnification, ×40)
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lymph node metastasis also was significantly associated with
distant metastasis and recurrence (P < 0.05).
Outcomes according to existing tumor staging systems
and evaluation standards
Analyses of the results in our study indicate that both the
pre-operative clinical FIGO stage (Fig. 2, Table 1) and post-
operative pathological FIGO stage can predict survival-
related outcomes (Table 1, Additional file 1: Figure S1). In
addition, the existing tumor evaluation standards, specific-
ally the WHO double diameter measurement evaluation
and the RECIST 1.1, were also correlated with the
outcomes of our patients (Additional file 2: Figures S2 &
Additional file 3: Figure S3 and Table 1). However, the TNR
and TRG failed to be prognostic indicators according to
Spearman tests (Table 1).
Outcomes according to TID and TIDC
Along with the factors identified in univariate analysis as
potentially influencing patient outcomes, we included the
TID (P < 0.05, relative hazard [RH] = 9.7, 95 % confidence
interval [CI] = 1.508–32.350) in the multivariate Cox pro-
portional hazard models as an independent prognostic fac-
tor due to a strong correlation with distant metastasis, PFS,
and OS. The results indicate that TID from the cervical in-
ternal surface represents a novel predictor of prognosis in
cervical carcinoma. Based on the statistical differences in
distant metastasis and survival outcomes according to TID,
a ROC curve was generated to investigate the best cut-off
value for classifying TID. From this curve, the best cut-off
value was found to be 3.75 mm. The same calculations for
TIDC resulted in an adjusted cut-off value of 4.75 mm. The
results of correlation analyses of patient data according to
these cut-off values are presented in Table 2.
TID or TIDC values less than the cut-off values could
represent two different situations: (1) a complete lack of re-
sidual tumor cells, and (2) a measurable invasion depth less
than the cut-off point. Correlation analysis indicated that
there were no statistical differences in outcomes related to
survival (P = 0.254) or distant metastasis (P = 0.212) be-
tween these situations. The same results were obtained for
TIDC, with no differences in outcomes related to survival
(P = 0.823) and distant metastasis (P = 0.412).
The prognostic value of the TID and TIDC cut-off
values for distant metastasis, PFS, and OS was confirmed
by Kaplan–Meier survival curves (Fig. 3). Thus, a TID
greater than 3.75 mm and a TIDC greater than 4.75 mm
on immunostained specimens indicate a higher relative
risk of distant metastasis and poor survival.
Because the results shown in Fig. 2 demonstrated that pa-
tients with pre-operative clinical FIGO stage IIIb cancer
had a lower 5-year survival rate than patients with other
stages and the Kaplan–Meier survival curves could not
show clear statistical differences between the survival out-
comes of stage Ib and II patients, we further analyzed the
predictive value of the TID and TIDC cut-off values exclud-
ing data for patients without the clinical stage IIIb carcin-
oma to eliminate the effects of the clinical stage of cervical
carcinoma. The results showed that these TID and TIDC
cut-off values were still prognostic indicators for PFS and
OS (Fig. 4).
Discussion
In this study, we assessed the prognostic value of different
clinical and pathologic assessment parameters using data of
173 cervical squamous cell carcinoma patients who under-
went neoadjuvant RT or CCRT prior to radical hysterec-
tomy. Although no standard procedures for neoadjuvant
therapy plus surgery have been confirmed yet and more
supporting data are still needed, especially data regarding
CCRT, some studies have suggested that pre-operative
CCRT is associated with significantly improved PFS and
OS compared with RT alone [21, 22], whereas other studies
have provided evidence suggesting almost the same clinical
outcomes following these different treatment modalities
[13, 23]. Our data also did not show significant differences
in the outcomes of patients who received RT alone or
CCRT, which is consistent with the results of the study by
Keys et al. [24]. Moreover, improvement of the 5-year OS
rate with neoadjuvant CCRT over that achieved with RT
alone remains to be proven. In our study, the 60.0 % 5-year
survival rate of stage IIIb patients is similar to the rates pre-
viously reported, whereas the 96.7 % 5-year survival rate of
Fig. 2 Association of overall survival (OS) and progression-free survival (PFS) with the pre-operative clinical FIGO stage. a OS and b PFS curves
show a slight difference with different pre-operative clinical FIGO staging prior to radical hysterectomy
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stage IIb patients in our study seems to be higher than rates
previously reported (e.g., 71.0 %) [25, 26]. These findings
may suggest the benefit of neoadjuvant RT or CCRT, but
further studies are still needed to draw such conclusions.
Before radical hysterectomy, we obtained the tumor size
measurements used in the clinical FIGO staging system
and WHO and RECIST 1.1 evaluation criteria by TVS
examination, which has been shown to be highly accurate
for detecting tumor presence and evaluating the local ex-
tension of cervical carcinoma [27, 28]. Because this imaging
technique is faster, cheaper, and more widely available than
other imaging techniques [27, 28], its use is consistent with
our objective of establishing prognostic criteria for cervical
carcinoma underwent neoadjuvant treatment that are easily
applied in most hospitals. However, TVS is a painful and
time-consuming procedure, especially for the patients who
have undergone RT or CCRT.
The FIGO staging system [16, 17], especially the re-
vised FIGO (2009) staging system, is widely used in
standard clinical and pathologic staging procedures for
many types of cancer, including cervical carcinoma.
Similar to the results of previous clinicopathologic stud-
ies on cervical carcinoma [29], our data demonstrate
that the clinical FIGO staging prior to radical hysterec-
tomy serves as a valuable independent predictor of dis-
tant metastasis and survival outcomes (Table 1 and
Fig. 2) in patients with FIGO stage III carcinomas,
whereas it is not a very effective predictor of outcomes
for stage I and II carcinomas. In addition, our results
showed that post-operative pathologic FIGO staging is a
less effective predictor compared with the clinical stage.
Use of the FIGO staging system both before and after
surgical treatment are dependent on the assessment of
tumor size and invasion of the parametrium and pelvic













P Recurrence (%) P The death
events in
5 years, n (%)
P
TID <3.75 104 (60.1 %) 45 (27–71) 4 (3.8 %) <0.001 12 (11.5 %) 0.991 1 (1.0 %) 0.064 1 (1.0 %) <0.001
>3.75 69 (39.9 %) 46 (25–65) 14 (20.2 %) 8 (11.6 %) 4 (5.8 %) 10 (14.5 %)
TIDC <4.75 100 (57.8 %) 45 (27–65) 4 (4.0 %) 0.001 12 (12.0 %) 0.834 1 (1.0 %) 0.083 1 (1.0 %) 0.001
>4.75 73 (42.2 %) 46 (25–71) 14 (19.2 %) 8 (11.0 %) 4 (5.5 %) 10 (13.7 %)
Fig. 3 Association of overall survival (OS) and progression-free survival (PFS) with the TID and TIDC at the cervical internal surface. a OS and b
PFS curves show a clear difference between patient outcomes according to a TID cut-off value of 3.75 mm (TID <3.75 mm and TID ≥3.75 mm). c
OS and d PFS curves show the prognostic significance of TIDC with the cut-off point of 4.75 mm (TIDC <4.75 mm and TIDC ≥4.75 mm)
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side wall as well as the evaluation of adjacent organs and
lymph node involvement [30]. Thus, high accuracy of
FIGO staging prior to radical hysterectomy for cervical
carcinoma prognosis is not easily obtainable and de-
pends heavily on accurate clinical examinations [28–32].
The WHO (double diameter measurement evaluation)
criteria and RECIST 1.1 criteria are widely used and also
were found to be effective in our study (Table 1 and
Additional file 2: Figure S2 & Additional file 3: Figure
S3). However, these two sets of criteria clearly state that
tumor lesions situated in a previously irradiated area, or
in an area subjected to other loco-regional therapy, are
not usually considered measurable unless evidence of
progression in the lesion has been demonstrated [31].
Moreover, both sets of criteria also suggest the ultra-
sound examinations should not be used for imaging-
based evaluation measurements, because ultrasound is
regarded as operator dependent and therefore of limited
reliability [32]. However, the effective application of
these two sets of criteria in our study indicated that the
use of TVS is more reliable than ordinary ultrasound
examination with respect to the accuracy of the results.
In our study, to find useful prognostic factors for cer-
vical carcinoma treated with neoadjuvant RT or CCRT,
we also included the TNR in our analyses and showed
that the TNR cannot be considered an effective prognos-
tic factor (Table 1). This is likely because the degree of
necrosis within tumor tissue is not apparent until some
time after treatment. Moreover, TNR also can be easily
affected by tumor heterogeneity, artery dilatation, and
vascular proliferation within the tumor [33]. We also ap-
plied the 5-point TRG scoring system to determine
whether the TRG is correlated with outcomes in these
patients. Based on the hypothesis that a shorter tumor
cell doubling time indicates a more aggressive tumor,
the regression grade is in general considered to be re-
lated to patients’ prognosis. However, the TNR is a sub-
jective criterion not based on an objective measurement
and thus does not offer good reproducibility, and our re-
sults showed no clear prognostic significance for patients
with cervical carcinoma treated with neoadjuvant ther-
apy (Table 1).
Residual tumor cells are generally considered aggressive,
and the area containing such cells may be important for
the determination of invasive and metastatic capacity.
Dipen et al. proposed “tumor thickness” as a new prog-
nostic factor for therapy response and survival outcome in
patients with resected hepatic colorectal metastases [34],
and other studies also indicated that the tumor thickness
remains the most important determinant of melanoma
patient survival [35, 36]. For cervical carcinoma, tumor
diameter and volume, as determined by pre-surgery im-
aging examinations, can predict progression-free survival
[37], and previous studies confirmed that the tumor size
on T2-weighted magnetic resonance images is a useful
index for evaluating parametrial involvement of cervical
Fig. 4 Upon removing the data for patients with a pre-operative clinical FIGO stage of IIIb, a OS and b PFS curves continue to show the significant
prognostic value of TID with a cut-off value of 3.75 mm. c OS and d PFS curves generated while excluding data for patients with stage IIIb carcinoma
also continue to demonstrate the prognostic significance of the TIDC with a cut-off value of 4.75 mm
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carcinoma with full-thickness stromal invasion [38].
Therefore, based on the hypothesis that the existence of
residual tumor cells correlates with the outcomes of pa-
tients, the TID was designed to measure the length per-
pendicular to the cervical internal surface in the maximal
cutting plane. Measurement of this dimension was less
time consuming and more reproducible, because few pa-
rameters are considered and major parts of the tumor
cannot be disregarded [34, 39].
In practice, nest-like or cord-like scattered tumor cells
and continuous tumor tissue invading to different depths
with different degrees of necrosis and inflammatory re-
actions can be identified easily under a microscope. Also,
the reproducibility of such objective measurements
could not be easily influenced by the pathologist’s ex-
perience. In the present study, cytokeratin immunostain-
ing was used to identify some uncertain residual tumor
tissue and obtain TIDC measurements. The positive re-
sults demonstrated the existence of residual tumor tissue
and inevitably changed the measured invasion depth.
Even after we eliminated the major influence of patients’
pre-operative clinical FIGO stages on survival outcomes,
both the TID and TIDC were found to be significantly
correlated with distant metastasis and survival outcomes
in cervical squamous cell carcinoma patients who had
undergone adjuvant RT or CCRT.
Conclusion
Pre-operative clinical FIGO staging as well as the WHO
double diameter measurement evaluation and RECIST
1.1 criteria, according to tumor size assessed by TVS
examination, were found to be useful predictive indica-
tors of patient outcomes following radical hysterectomy
in cervical squamous carcinoma patients who underwent
neoadjuvant RT or CCRT. However, in addition to these
previously reported assessment standards and methods,
our results also provide evidence that the TID or TIDC at
the cervical internal surface is a useful and easily applied
prognostic factor for distant metastasis and survival out-
comes in these patients, irrespective of pre-operative
FIGO staging.
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